Table 1.

Estimation of the risk of severe TBE in auto-Ab-positive individuals relative to the general population

Anti-type I IFN auto-Ab (amount of type I IFN neutralized, in plasma diluted 1:10)	OR (95% CI)	P value
Anti-IFN-α2 (10 ng/ml)	8.1 (1.8–37.4)	0.0005565
Anti-IFN-ω (10 ng/ml)	12.3 (3.0–51.4)	0.0000022
Anti-IFN-α2 (10 ng/ml) and/or anti-IFN-ω (10 ng/ml) and/or anti-IFN-β (10 ng/ml)	8.7 (2.3–33.7)	0.0000053
Anti-IFN-α2 (10 ng/ml) and anti-IFN-ω (10 ng/ml)	20.8 (4.5–97.4)	0.0000009
Anti-IFN-α2 (100 pg/ml)	2.9 (0.6–13.5)	0.0726972
Anti-IFN-ω (100 pg/ml)	7.2 (2.1–24.4)	0.0000002
Anti-IFN-α2 (100 pg/ml) and/or anti-IFN-ω (100 pg/ml) and/or anti-IFN-β (10 ng/ml)	4.9 (1.5–15.9)	0.0000113
Anti-IFN-α2 (100 pg/ml) and anti-IFN-ω (100 pg/ml)	7.4 (1.6–34.3)	0.0011799